Introduction to the Conference
Welcome/Overview
As more becomes known about bipolar disorder, its etiology,
diagnosis, and treatment, the International Conference on Bipolar Disorder has
emerged as an important vehicle for the dissemination of information on the
subject. Each of the previous conferences has seen an increasing number of
researchers, academicians, and clinicians gather to discuss the latest advances
in Bipolar Disorder research as presented by leading international experts. The
Fourth International Conference on Bipolar Disorder will present information on:
- New approaches to treatment.
- Recent findings in pharmacotherapy and neuroscience.
- Child and adolescent bipolar disorder.
- Multi-site treatment trials.
- Regulatory issues in developing drug treatments for bipolar
disorder.
Presentations during the first two days of the conference will be
technical and geared toward academic researchers and research-oriented
clinicians. Psychiatrists, psychologists, neuroscientists and pharmacologists
interested in bipolar disorder should find the content of the first phase of the
conference useful in their research and practice.
As in the past, the conference will also feature "Ask the
Experts" question and answer sessions, and posters will be displayed on
Thursday, June 14 and Friday, June 15. A new addition to the conference will be
"Rapid Communications" sessions each day.
Along with these noted sessions, the third day of the conference
will include an international advocacy forum and psychosocial treatment
workshops focusing on cognitive therapy, family therapy, and interpersonal and
social rhythm therapy. This third day will be appropriate for audiences that
include psychiatrists, psychologists, social workers, nurses, and other mental
health care workers as well as individuals who have bipolar disorder and their
families.
At the close of the program, participants should be able to:
1. Describe new approaches to the pharmacotherapy and
psychotherapy of bipolar disorder.
2. Identify key issues in the regulation of psychopharmacologic
drugs in the United States and Europe.
3. Describe the range of multi-site treatment trials being
conducted worldwide as well as early results from these trials. We look forward
to your participation in the conference.
David J. Kupfer, M.D.
Course Directors
Ellen Frank, Ph.D.
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Samuel A.
Gershon, M.D.
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
David J. Kupfer,
M.D.
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Alan G. Mallinger,
M.D.
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Michael E. Thase,
M.D.
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
International Planning
Committee
Giovanni de Girolamo,
M.D.
National
Institute of Health
National Mental
Health Project
Rome, Italy
Guy Goodwin, M.D.
University
Department of Psychiatry
Warneford
Hospital
Oxford,
United Kingdom
Fouzia Laghrissi-Thode,
M.D.
F. Hoffman-LaRoche
Ltd.
Basel,
Switzerland
Bruno
Müller-Oerlinghausen, Dr.med.
Research
Group Clinical Psychopharmacology
Department of Psychiatry
Freie Universitaet Berlin
Berlin,
Germany
Per Vestergaard,
Dr.Med.Sc.
Aarhus
University, Psychiatric Hospital
Risskov,
Denmark
Faculty
Jules Angst, M.D.
Psychiatric
University Hospital
Zurich,
Switzerland
David A. Axelson, M.D.
University of
Pittsburgh School of Medicine
Pittsburgh,
Pennsylvania
Mark S. Bauer, M.D.
Brown
University
School of Medicine
Providence VA Medical Center
Providence, Rhode
Island
Boris Birmaher, M.D.
University of
Pittsburgh School of Medicine
Pittsburgh,
Pennsylvania
Giovanni B. Cassano, M.D.
University of
Pisa
Pisa, Italy
Paula J. Clayton, M.D.
University of
Minnesota Medical
School
Minneapolis, Minnesota
University of New Mexico
School of Medicine
Albuquerque, New
Mexico
Rodney Elgie
GAMIAN-Europe
Kent, United Kingdom
Barbara Geller, M.D.
Washington University
School of Medicine in St. Louis
St. Louis, Missouri
Valentim Gentil, M.D.,
Ph.D.
University of
Sao Paulo Medical
School
Sao Paulo, Brazil
Earl L. Giller, Jr.,
M.D., Ph.D.
Pfizer, Inc.
New York, New
York
Giovanni de Girolamo,
M.D.
Guy Goodwin, M.D.
Frederick K. Goodwin,
M.D.
George
Washington University
Medical
Center
Washington, D.C.
Ian M. Goodyer, M.D. F.Med.Sci.
Cambridge
University
Cambridge, United
Kingdom
Noreen Reilly Harrington,
Ph.D.
Harvard
Medical
School
Boston,
Massachusetts
Paul Harrison, M.D.,
M.R.C.Psych.
University Department of Psychiatry
Warneford Hospital
Oxford,
United Kingdom
Martha Hellander
Child and
Adolescent Bipolar Foundation
Wilmette,
Illinois
Steven E. Hyman, M.D.
National
Institute of Mental Health
Bethesda,
Maryland
Hilkka Kärkkäinen
Central
Association of Mental Health
Helsinki,
Finland
Paul E. Keck, Jr., M.D.
University of
Cincinnati
College
of Medicine
Cincinnati, Ohio
Athanasio Koukopoulos,
M.D.
Centro Lucio
Bini
Rome, Italy
Robert A. Kowatch, M.D.
University of
Cincinnati
Medical
Center
Cincinnati, Ohio
Fouzia Laghrissi-Thode,
M.D.
Thomas P. Laughren, M.D.
U.S. Food and
Drug Administration
Rockville, Maryland
Barry D. Lebowitz, Ph.D.
National
Institute of Mental Health
Bethesda,
Maryland
Lydia Lewis
National
Depressive and Manic-Depressive Association
Chicago,
Illinois
Patrick McKeon, M.D.,
F.R.C.P.I., F.R.C.Psych.
Aware Defeat
Depression
Dublin,
Ireland
Alan Metz, M.D.
GlaxoSmithKline
Research Triangle Park, North Carolina
David Miklowitz, Ph.D.
University of
Colorado
at
Boulder
Boulder,
Colorado
Paolo Lucio Morselli,
M.D.
Fondazione
IDEA and GAMIAN-Europe
Milan, Italy
Bruno
Müller-Oerlinghausen, Dr.med.
Willem A. Nolen, M.D.,
Ph.D.
Altrecht
Institute for Mental Health Care
University
Medical
Center Utrecht
Utrecht, The Netherlands
Michael Otto, Ph.D.
Harvard
Medical
School
Boston,
Massachusetts
Atul Pande, M.D.,
F.R.C.P.C.
Pfizer Global
Research and Development
Ann Arbor, Michigan
Robert M. Post, M.D.
National
Institute of Mental Health
Bethesda,
Maryland
Catrien Reichart, M.D.
Academisch
Ziekenhuis Rotterdam
Rotterdam, The Netherlands
A. John Rush, M.D.
The
University of
Texas
Southwestern
Medical
Center at Dallas
Dallas, Texas
Gary S. Sachs, M.D.
Harvard
Medical
School
Boston,
Massachusetts
Amy Schlonski, M.S.W.
Western
Psychiatric Institute and Clinic
Pittsburgh, Pennsylvania
Greg Simon, M.D., M.P.H.
Center for
Health Sciences
Seattle,
Washington
Jair C. Soares, M.D.
University of
Pittsburgh
School
of Medicine
Pittsburgh,
Pennsylvania
Jitschak Storosum, M.D.
Medicines
Evaluation Board of The Netherlands
Den Haag, The Netherlands
Leonardo Tondo, M.D.
Harvard
Medical
School
Boston,
Massachusetts
University of
Cagliari
Cagliari, Italy
Per Vestergaard,
Dr.Med.Sc.
Adele Viguera, M.D.
Harvard
Medical
School
Boston,
Massachusetts
Susan Wassick, R.N.
Western
Psychiatric Institute and Clinic
Pittsburgh, Pennsylvania
Robert M. Wettstein, M.D.
University of
Pittsburgh
School
of Medicine
Pittsburgh,
Pennsylvania
Rapid Communications Session Speakers
Martin Alda, M.D., FRCP(C)
Dalhousie
University
Halifax, Nova
Scotia, Canada
Joseph R. Calabrese, M.D.
Case
Western Reserve University
School
of Medicine
Cleveland, Ohio
Paolo Cassano, M.D.
University of
Pisa
Pisa, Italy
Lisa C. Goodale, M.S.W.
National
Depressive and Manic-Depressive Association (NDMDA)
Chicago,
Illinois
Nancy Honeycutt, Ph.D.
The Johns
Hopkins University
School of Medicine
Baltimore,
Maryland
Frederic J. Kochman, M.D.
EPSM
Agglomeration Lilloise
St. Andre, Lille,
France
Dominic Lam, Ph.D.
Institute of
Psychiatry
De Crespigny Park
London,
United Kingdom
Rasmus W. Licht, M.D.,
Ph.D.
Aarhus
Psychiatric
University
Hospital
Risskov,
Denmark
Paul J. Monks, M.B.,
BCHIR, MRCPSYCH
Institute of
Psychiatry
De Crespigny Park
London,
United Kingdom
Emanuela Mundo, M.D.
University of
Toronto
Toronto,
Ontario, Canada
Jan Scott, M.D., FRCPsych
University of
Glasgow
Gartnavel
Royal
Hospital
Glasgow,
United Kingdom
Sjacko Sobczak, M.Sc.
Brain and
Behavior Institute
Maastricht, The Netherlands
Dietrich O. van Calker,
Ph.D., M.D.
University of
Freiburg
Freiburg,
Germany
Disclosure Statement
In accordance with the policies
on disclosure of the Accreditation Council for Continuing Medical Education and
the University of Pittsburgh Faculty Advisory Committee for Continuing Medical
Education in the Health Sciences, presenters for this program, have been
requested to identify significant financial or other relationships with
manufacturer(s) of any commercial product(s) or with providers(s) of any
commercial service(s) which, in the context of their topics, could be perceived
as real or apparent conflicts of interest. The following information was
disclosed:
Joseph R. Calabrese, M.D.
| Grant/Research
Support |
Abbott Laboratories
CIBA-GEIBY
E-Merck
Forest Laboratories
Glaxo-Wellcome Pharmaceuticals
Lilly Research Laboratories
MacArthur Foundation
National Alliance for Research in
Schizophrenia and Affective
Disorders
National Institute of Mental Health
Parke-Davis Pharmaceuticals
Robert Wood Johnson
Pharmaceutical Research Institute
Sandoz Pharmaceuticals Corporation
SmithKline Pharmaceuticals
Stanley Foundation
Tap Holdings, Inc.
UCB Pharma
Wyeth Ayerst Pharmaceuticals |
|
Consultant
|
Abbott Laboratories
AstraZeneca
Elan Pharmaceuticals
Eli Lilly and Company
Glaxo-Wellcome Pharmaceuticals
Janssen Cilag
Novartis
Parke-Davis Pharmaceuticals
Robert Wood Johnson
Pharmaceutical Research Institute
Shire Labs
SmithKline Pharmaceuticals
TAP Holdings
Teva Pharmaceuticals
UCB |
Paula J. Clayton, M.D.
| Speakers' Bureau |
Forest Laboratories
Eli Lilly and Company |
|
Stockholder
|
Minor in:
Forest Laboratories
Eli Lilly and Company
Merck & Company, Inc. |
Ellen Frank, Ph.D.
| Grant/Research Support |
Eli Lilly and Company
National Institute of Mental Health
|
| Consultant |
Forest Laboratories
Eli Lilly and Company
Pfizer, Inc. U.S.A.
Pfizer Italia |
Barbara Geller, M.D.
| Grant/Research
Support |
Layton Bioscience (Pending) |
|
Speakers' Bureau |
Solvay Pharmaceuticals |
Samuel A. Gershon, M.D.
Earl L. Giller, Jr., M.D., Ph.D.
| Other Financial or
Material Support |
Employee, Pfizer, Inc.
|
Frederick K. Goodwin, M.D.
| Grant/Research
Support |
Abbott Laboratories |
|
Consultant |
Glaxo-Wellcome Pharmaceuticals
Eli Lilly and Company
Pfizer, Inc.
Scios |
|
Speakers' Bureau |
Glaxo-Wellcome Pharmaceuticals
Janssen Pharmaceutica
Eli Lilly and Company
Pfizer, Inc.
Scios |
Guy Goodwin, M.D.
| Consultant |
Janssen Pharmaceutica
Eli Lilly and Company
Pfizer, Inc.
Sanofi |
| Other Financial or
Material Support |
Eli Lilly and Company
(to attend meetings) |
Paul E. Keck, Jr., M.D.
| Grant Research
Support |
Abbott Laboratories
AstraZeneca
Janssen Pharmaceutica
Eli Lilly and Company
Merck & Company, Inc.
Pfizer, Inc.
|
| Consultant |
Abbott Laboratories
AstraZeneca
Bristol-Myers Squibb Company
Janssen Pharmaceutica
Eli Lilly and Company
Pfizer, Inc. |
Robert A. Kowatch, M.D.
| Consultant |
Abbott Laboratories
Johnson & Johnson
|
| Speakers' Bureau |
Abbott Laboratories
Solvay Pharmaceuticals |
David J. Kupfer, M.D.
| Consultant |
Hoffman-LaRoche
|
| Other Financial or
Material Support |
Advisory Boards:
Forest Laboratories
Eli Lilly and Company
Pfizer, Inc.
|
Fouzia Laghrissi-Thode, M.D.
|
Other Financial or Material Support
|
Hoffman-LaRoche |
Rasmus W. Licht, M.D., Ph.D.
|
Other Financial or Material Support
|
GlaxoSmithKline |
Alan G. Mallinger, M.D.
|
Grant/Research Support
|
Solvay Pharmaceuticals |
Alan Metz, M.D.
|
Stockholder/Employee
|
GlaxoSmithKline |
Willem A. Nolen, M.D., Ph.D.
| Grant/Research
Support |
Stanley Foundation |
|
Consultant |
Glaxo-Wellcome Pharmaceuticals
Janssen-Cilag
Eli Lilly and Company
Sanofi-Synthelabo |
Michael Otto, Ph.D.
| Grant/Research
Support |
Eli Lilly and Company
Pfizer, Inc. |
|
Consultant |
Ancile
Janssen Pharmaceutica
Pharmacia & Upjohn |
Atul Pande, M.D., F.R.C.P.C.
| Stockholder |
Pfizer, Inc. |
|
Other Financial or Material Support
|
Employee of Pfizer, Inc. |
Robert M. Post, M.D.
| Consultant |
Abbott Laboratories
Glaxo-Wellcome Pharmaceuticals
Janssen
Novartis
Pfizer, Inc.
UCB Pharma |
A. John Rush, M.D.
| Grant/Research Support |
Abbott Laboratories
Bristol-Myers Squibb Company
Cyberonics, Inc.
Forest Pharmaceuticals/Parke Davis
Glaxo-Wellcome Pharmaceuticals
Janssen Pharmaceutica
Robert Wood Johnson Foundation
Eli Lilly and Company
Meadows Foundation
National Institute of Mental Health
Novartis
Organon, Inc.
Pfizer, Inc.
Pharmacia & Upjohn
SmithKline Beecham
Pharmaceuticals
Stanley Foundation
Wyeth Ayerst Laboratories
Zeneca |
| Consultant |
Bristol-Myers Squibb Company
Cyberonics, Inc.
Forest Pharmaceuticals/Parke Davis
Glaxo-Wellcome Pharmaceuticals
Janssen Pharmaceutica
Eli Lilly and Company
Merck & Company, Inc.
Mitsubishi Pharmaceuticals
National Institute of Mental Health
Organon, Inc.
Pfizer, Inc.
Pharmacia & Upjohn
Stanley Foundation
Wyeth Ayerst Laboratories
Yamanouchi, Inc. |
| Speakers' Bureau |
Abbott Laboratories
Bristol-Myers Squibb Company
Cyberonics, Inc.
Forest Pharmaceuticals/Parke Davis
Glaxo-Wellcome Pharmaceuticals
Eli Lilly and Company
Organon, Inc.
Pfizer, Inc.
Pharmacia & Upjohn
Wyeth Ayerst Laboratories |
Gary S. Sachs, M.D.
| Grant/Research Support |
Abbott Laboratories
Glaxo-Wellcome Pharmaceuticals
Janssen Pharmaceutica
Eli Lilly and Company
|
| Consultant |
Abbott Laboratories
Bristol-Myers Squibb Company
Elan
Glaxo-Wellcome Pharmaceuticals
Janssen Pharmaceutica
Eli Lilly and Company
Novartis
Sanofi
Scios
|
| Other Financial or
Material Support |
Honoraria from:
Abbott Laboratories
Bristol-Myers Squibb
Glaxo-Wellcome Pharmaceuticals
Janssen Pharmaceutica
Eli Lilly and Company
Novartis
Sanofi
Scios
Solvay Pharmaceuticals
|
Jan Scott, M.D., FRCPsych
| Grant/Research
Support |
British Medical Research Council
Theodore and Vada Stanley |
Greg Simon, M.D., M.P.H.
| Grant/Research
Support |
Abbott Laboratories (Inactive)
Eli Lilly and Company
Pfizer, Inc. (Inactive)
Searle (Inactive) |
Jair C. Soares, M.D.
| Speakers' Bureau |
Eli Lilly and Company
Pfizer, Inc.
Solvay |
Michael E. Thase, M.D.
| Grant/Research Support |
Bristol-Myers Squibb Company
Merck & Company, Inc.
Organon, Inc.
Pharmacia & Upjohn
Wyeth Ayerst Laboratories
|
| Consultant |
Bristol-Myers Squibb Company
Forest Pharmaceuticals
Glaxo-Wellcome Inc./
Cerenex Pharmaceuticals
Eli Lilly and Company
Merck & Company, Inc.
Organon, Inc.
Pfizer, Inc.
Pharmacia & Upjohn
WyethAyerst Laboratories
|
| Speakers' Bureau |
Bristol-Myers Squibb Company
Forest Pharmaceuticals
Glaxo-Wellcome Inc./
Cerenex Pharmaceuticals
Eli Lilly and Company
Organon, Inc.
Parke-Davis Pharmaceuticals
Pfizer, Inc.
Pharmacia & Upjohn
SmithKline Beecham
Solvay Pharmaceuticals
Wyeth Ayerst Laboratories
|
Dietrich O. van Calker, Ph.D.,
M.D.
|
Grant Research Support
|
Pfizer, Inc. (Travel Expenses) |
Adele Viguera, M.D.
| Speakers' Bureau |
Eli Lilly and Company |
No significant financial relationships with
commercial entities were disclosed by:
Martin Alda, M.D., FRCP(C)
Jules Angst, M.D.
David A. Axelson, M.D.
Mark S. Bauer, M.D.
Boris Birmaher, M.D.
Giovanni B. Cassano, M.D.
Paolo Cassano, M.D.
Rodney Elgie
Valentim Gentil, M.D., Ph.D.
Giovanni de Girolamo, M.D.
Lisa C. Goodale, M.S.W.
Ian M. Goodyer, M.D. F.Med.Sci.
Noreen Reilly Harrington, Ph.D.
Paul Harrison, M.D.
Martha Hellander
Nancy Honeycutt, Ph.D.
Steven E. Hyman, M.D.
Hilkka Karkkainen
Frederic J. Kochman, M.D.
Athanasio Koukopoulos, M.D.
Dominic Lam, Ph.D.
Thomas P. Laughren, M.D.
Barry D. Lebowitz, Ph.D.
Lydia Lewis
Patrick McKeon, M.D.
David Miklowitz, Ph.D.
Paul J. Monks, M.B., BCHIR, MRCPSYCH
Paolo Lucio Morselli, M.D.
Bruno Muller-Oerlinghausen, Dr.med.
Emanuela Mundo, M.D.
Catrien Reichart, M.D.
Amy Schlonski, M.S.W.
Sjacko Sobczak, M.Sc.
Jitschak Storosum, M.D.
Leonardo Tondo, M.D.
Per Vestergaard, Dr.Med.Sc.
Susan Wassick, R.N.
Robert M. Wettstein, M.D.
The information presented at this CME program
represents the views and opinions of the individual presenters, and does not
constitute the opinion or endorsement of, or promotion by, the UPMC Center for
Continuing Education in the Health Sciences, UPMC Health System or Affiliates
and University of Pittsburgh School of Medicine. Reasonable efforts have been
taken intending for educational subject matter to be presented in a balanced,
unbiased fashion and in compliance with regulatory requirements. However, each
program attendee must always use his/her own personal and professional judgment
when considering further application of this information, particularly as it may
relate to patient diagnostic or treatment decisions including, without
limitation, FDA-approved uses and any off-label uses.
Acknowledgements
We would like to acknowledge the
following companies for their generous support of this program: Abbott
Laboratories, AstraZeneca, Forest Laboratories, Inc., Glaxo-Wellcome, Janssen Pharmaceutica, Eli
Lilly and Company, Pfizer, Inc., Solvay Pharmaceuticals, and Wyeth Ayerst
Pharmaceuticals.
Top of Page
|
